IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 201–300 of 1,011
Blomberg, O. S., Spagnuolo, L., Garner, H., Voorwerk, L., Isaeva, O. I., van Dyk, E., Bakker, N., Chalabi, M., Klaver, C., Duijst, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.11.014 · Cited by 212
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
“a) T cell-inflamed gene expression profile (GEP) is one of the early reported and clinically validated gene signatures for predicting response to pembrolizumab across multiple solid tumors (93).”
BackgroundCurrent status of immune checkpoint inhibitors for gastric cancer
Kono, K., Nakajima, S., & Mimura, K. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01090-4 · Cited by 220
Marinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2105 · Cited by 221
Hotz, C., Wagenaar, T. R., Gieseke, F., Bangari, D. S., Callahan, M., Cao, H., Diekmann, J., Diken, M., Grunwitz, C., Hebert, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7804 · Cited by 215
Higgs, B. W., Morehouse, C. A., Streicher, K., Brohawn, P. Z., Pilataxi, F., Gupta, A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 220
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 216
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A., & Lesterhuis, W. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960317 · Cited by 197
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01315-x · Cited by 218
Vadakekolathu, J., Minden, M. D., Hood, T., Church, S. E., Reeder, S., Altmann, H., Sullivan, A. H., Viboch, E. J., Patel, T., Ibrahimova, N., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz0463 · Cited by 216
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
Jing, Y., Liu, J., Ye, Y., Pan, L., Deng, H., Wang, Y., Yang, Y., Diao, L., Lin, S. H., Mills, G. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18742-9 · Cited by 215
Wise-Draper, T. M., Gulati, S., Palackdharry, S., Hinrichs, B. H., Worden, F. P., Old, M. O., Dunlap, N. E., Kaczmar, J. M., Patil, Y., Riaz, M. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3351 · Cited by 197
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Zemek, R. M., De Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S. J., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 212
The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
Ng, S. S., De Labastida Rivera, F., Yan, J., Corvino, D., Das, I., Zhang, P., Kuns, R., Chauhan, S. B., Hou, J., Li, X.-Y., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0758-6 · Cited by 221
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02231-0 · Cited by 209
A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
Xiong, D., Wang, Y., & You, M. (2020) · Nature Communications · doi:10.1038/s41467-020-18546-x · Cited by 208
Wu, Y., Kyle-Cezar, F., Woolf, R. T., Naceur-Lombardelli, C., Owen, J., Biswas, D., Lorenc, A., Vantourout, P., Gazinska, P., Grigoriadis, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax9364 · Cited by 199
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Sun, H., Liu, S.-Y., Zhou, J.-Y., Xu, J.-T., Zhang, H.-K., Yan, H.-H., Huan, J.-J., Dai, P.-P., Xu, C.-R., Su, J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102990 · Cited by 206
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Jiang, S., Liu, Y., Zheng, H., Zhang, L., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000492 · Cited by 189
TIGIT: a novel immunotherapy target moving from bench to bedside
Solomon, B. L., & Garrido-Laguna, I. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2246-5 · Cited by 200
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
Wan, C., Keany, M. P., Dong, H., Al-Alem, L. F., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1674 · Cited by 193
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
Tímár, J., & Ladányi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105384 · Cited by 164
The Immune Subtypes and Landscape of Squamous Cell Carcinoma
Li, B., Cui, Y., Nambiar, D. K., Sunwoo, J. B., & Li, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4085 · Cited by 197
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park, Y. H., Lal, S., Lee, J. E., Choi, Y.-L., Wen, J., Ram, S., Ding, Y., Lee, S.-H., Powell, E., Lee, S. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19933-0 · Cited by 186
Biomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 183
He, B., Dong, D., She, Y., Zhou, C., Fang, M., Zhu, Y., Zhang, H., Huang, Z., Jiang, T., Tian, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000550 · Cited by 190
“19 However, all these potential biomarkers require an invasive biopsy combined with time-consuming and labour-intensive laboratory and clinical testing.”
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Kargl, J., Zhu, X., Zhang, H., Yang, G. H. Y., Friesen, T. J., Shipley, M., Maeda, D. Y., Zebala, J. A., McKay-Fleisch, J., Meredith, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130850 · Cited by 190
“Thus far, 5 major markers of favorable response to ICI treatment have been identified for NSCLC patients: (a) cigarette smoke consumption (7), (b) advanced mutational spectral burden (8), (c) CD8+ T cell infiltration into malignant tumor (9), (d) the IFN-γ signature (10), and (e) PDL1 staining by IHC > 50% (5).”
BackgroundChen, J. H., Nieman, L. T., Spurrell, M., Jorgji, V., Elmelech, L., Richieri, P., Xu, K. H., Madhu, R., Parikh, M., Zamora, I., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01792-2 · Cited by 174
Newman, J. H., Chesson, C. B., Herzog, N. L., Bommareddy, P. K., Aspromonte, S. M., Pepe, R., Estupinian, R., Aboelatta, M. M., Buddhadev, S., Tarabichi, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904022116 · Cited by 187
“An immunologically inflamed (“hot”) tumor microenvironment exhibits robust antigen presentation and T cell activation, contributing to the development of tumor-specific CD8 T cell functionality that can acutely eliminate cancer cells, generate systemic tumor-specific immunity, and form long-term antitumor memory respo…”
BackgroundImmunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 190
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
Franke, A. J., Skelton, W. P., Starr, J. S., Parekh, H., Lee, J. J., Overman, M. J., Allegra, C., & George, T. J. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz093 · Cited by 183
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D., & Merad, M. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 170
Biomarkers for immunotherapy in bladder cancer: a moving target
Aggen, D. H., & Drake, C. G. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0299-1 · Cited by 187
Integrated genomic profiling expands clinical options for patients with cancer
Beaubier, N., Bontrager, M., Huether, R., Igartua, C., Lau, D., Tell, R., Bobe, A. M., Bush, S., Chang, A. L., Hoskinson, D. C., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0259-z · Cited by 187
Luke, J. J., Piha-Paul, S. A., Medina, T., Verschraegen, C. F., Varterasian, M., Brennan, A. M., Riese, R. J., Sokolovska, A., Strauss, J., Hava, D. L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0118 · Cited by 173
Self-citationLiu, H., Zhang, W., Zhang, Y., Adegboro, A. A., Fasoranti, D. O., Dai, L., Pan, Z., Liu, H., Xiong, Y., Li, W., et al. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.06.035 · Cited by 176
Wu, V., Yeerna, H., Nohata, N., Chiou, J., Harismendy, O., Raimondi, F., Inoue, A., Russell, R. B., Tamayo, P., & Gutkind, J. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.005601 · Cited by 179
Liu, Z., Guo, C., Dang, Q., Wang, L., Liu, L., Weng, S., Xu, H., Lu, T., Sun, Z., & Han, X. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103750 · Cited by 181
Tumor immune microenvironment in head and neck cancers
Chen, S. M. Y., Krinsky, A. L., Woolaver, R. A., Wang, X., Chen, Z., & Wang, J. H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23162 · Cited by 179
Liu, X.-D., Kong, W., Peterson, C. B., McGrail, D. J., Hoang, A., Zhang, X., Lam, T., Pilie, P. G., Zhu, H., Beckermann, K. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15959-6 · Cited by 177
Chen, H., Chong, W., Wu, Q., Yao, Y., Mao, M., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01113 · Cited by 180
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 180
“expression) had higher levels of targetable immune checkpoints and markers of an active immune microenvironment that are associated with clinical responses to immunotherapy (6, 34) (Figure 5A).”
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Xu, Q., Chen, S., Hu, Y., & Huang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.711433 · Cited by 180
Ribas, A., Medina, T., Kirkwood, J. M., Zakharia, Y., Gonzalez, R., Davar, D., Chmielowski, B., Campbell, K. M., Bao, R., Kelley, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0425 · Cited by 180
Self-citationLow-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer
Song, M., Ping, Y., Zhang, K., Yang, L., Li, F., Zhang, C., Cheng, S., Yue, D., Maimela, N. R., Qu, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0596 · Cited by 163
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
Desrichard, A., Kuo, F., Chowell, D., Lee, K.-W., Riaz, N., Wong, R. J., Chan, T. A., & Morris, L. G. T. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy060 · Cited by 176
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., Joseph, R. W., Daud, A. I., Conry, R. M., Gaughan, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0309 · Cited by 171
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X.-S. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 180
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176
Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui, M., Cooper, T. J., Kalkar, P., Schif-Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Menachem, R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.005 · Cited by 165
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
“Since IFN signatures have been associated with responsiveness to immunotherapy (Ayers et al., 2017; Cristescu et al., 2018), these SNPs may also be associated with efficacy among patients receiving immunotherapy, which is consistent with preliminary data in melanoma patients receiving checkpoint inhibitors (Chat et al.”
ResultReschke, R., Yu, J., Flood, B. A., Higgs, E. F., Hatogai, K., & Gajewski, T. F. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003521 · Cited by 169
Hua, Y., Vella, G., Rambow, F., Allen, E., Antoranz Martinez, A., Duhamel, M., Takeda, A., Jalkanen, S., Junius, S., Smeets, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.002 · Cited by 169
Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B., Tan, L., Lorenzi, P. L., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0430 · Cited by 171
Jelinic, P., Ricca, J., Van Oudenhove, E., Olvera, N., Merghoub, T., Levine, D. A., & Zamarin, D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx277 · Cited by 168
Wang, J., Sun, H., Zeng, Q., Guo, X.-J., Wang, H., Liu, H.-H., & Dong, Z.-Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-49771-0 · Cited by 166
Cristescu, R., Aurora-Garg, D., Albright, A., Xu, L., Liu, X. Q., Loboda, A., Lang, L., Jin, F., Rubin, E. H., Snyder, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003091 · Cited by 164
Self-citationSchöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003776 · Cited by 163
Toki, M. I., Merritt, C. R., Wong, P. F., Smithy, J. W., Kluger, H. M., Syrigos, K. N., Ong, G. T., Warren, S. E., Beechem, J. M., & Rimm, D. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0104 · Cited by 167
Anti-tumour immunity induces aberrant peptide presentation in melanoma
Bartok, O., Pataskar, A., Nagel, R., Laos, M., Goldfarb, E., Hayoun, D., Levy, R., Körner, P.-R., Kreuger, I. Z. M., Champagne, J., et al. (2021) · Nature · doi:10.1038/s41586-020-03054-1 · Cited by 161
Zhou, X., Singh, M., Sanz Santos, G., Guerlavais, V., Carvajal, L. A., Aivado, M., Zhan, Y., Oliveira, M. M. S., Westerberg, L. S., Annis, D. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1741 · Cited by 169
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Lane, R. S., Femel, J., Breazeale, A. P., Loo, C. P., Thibault, G., Kaempf, A., Mori, M., Tsujikawa, T., Chang, Y. H., & Lund, A. W. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180654 · Cited by 165
“Scores were calculated as the first principal component of each gene set: LS, VEG FC, LYVE1, and PDPN; T cell inflammation score: CD8A, CCL2, CCL3, CCL4, CXCL9, CXCL10, ICOS, GZMK, IRF1, HLA-DMA, HLA-DMB, HLA-DOA, and HLADOB (Spranger et al., 2015); type II IFN score: IFNΓ, STAT1, CCR5, CXCL9, PRF1, HLA-DRA, CXCL10, C…”
Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
Cancer stem cell mimicry for immune evasion and therapeutic resistance
Saw, P. E., Liu, Q., Wong, P., & Song, E. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.06.003 · Cited by 183
Mondello, P., Tadros, S., Teater, M., Fontan, L., Chang, A. Y., Jain, N., Yang, H., Singh, S., Ying, H.-Y., Chu, C.-S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0116 · Cited by 167
Molecular determinants of response to PD-L1 blockade across tumor types
Banchereau, R., Leng, N., Zill, O., Sokol, E., Liu, G., Pavlick, D., Maund, S., Liu, L.-F., Kadel, E., Baldwin, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24112-w · Cited by 164
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Kline, J., Godfrey, J., & Ansell, S. M. (2020) · Blood · doi:10.1182/blood.2019000847 · Cited by 167
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
Owonikoko, T. K., Dwivedi, B., Chen, Z., Zhang, C., Barwick, B., Ernani, V., Zhang, G., Gilbert-Ross, M., Carlisle, J., Khuri, F. R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.006 · Cited by 166
Newell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165
Wang, T., Lu, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1246 · Cited by 168
Head and neck cancer: Current challenges and future perspectives
Bhat, G. R., Hyole, R. G., & Li, J. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.05.002 · Cited by 203
Melaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., De Vito, R., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 158
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
Cerezo-Wallis, D., Contreras-Alcalde, M., Troulé, K., Catena, X., Mucientes, C., Calvo, T. G., Cañón, E., Tejedo, C., Pennacchi, P. C., Hogan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1073-3 · Cited by 162
Dummer, R., Brase, J. C., Garrett, J., Campbell, C. D., Gasal, E., Squires, M., Gusenleitner, D., Santinami, M., Atkinson, V., Mandalà, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30062-0 · Cited by 161
Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 189
PAK4 inhibition improves PD-1 blockade immunotherapy
Abril-Rodriguez, G., Torrejon, D. Y., Liu, W., Zaretsky, J. M., Nowicki, T. S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M. J., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0003-0 · Cited by 157
Self-citationBullock, A. J., Schlechter, B. L., Fakih, M., Tsimberidou, A. M., Grossman, J. E., Gordon, M. S., Wilky, B. A., Pimentel, A., Mahadevan, D., Balmanoukian, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03083-7 · Cited by 181
Trujillo, J. A., Luke, J. J., Zha, Y., Segal, J. P., Ritterhouse, L. L., Spranger, S., Matijevich, K., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0780-0 · Cited by 159
Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3577 · Cited by 158
Zhang, S., Kohli, K., Black, R. G., Yao, L., Spadinger, S. M., He, Q., Pillarisetty, V. G., Cranmer, L. D., Van Tine, B. A., Yee, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0940 · Cited by 154
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
Zeng, D., Ye, Z., Wu, J., Zhou, R., Fan, X., Wang, G., Huang, Y., Wu, J., Sun, H., Wang, M., et al. (2020) · Theranostics · doi:10.7150/thno.46176 · Cited by 159
Vadakekolathu, J., Lai, C., Reeder, S., Church, S. E., Hood, T., Lourdusamy, A., Rettig, M. P., Aldoss, I., Advani, A. S., Godwin, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002512 · Cited by 154
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 177
“10,11 (C) Growth kinetics (left) of male KP cells grown in female hosts following antibody-mediated depletion of CD4 or CD8 T lymphocytes with endpoint lung weights (right).”
BackgroundSceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M., Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1454 · Cited by 156
Miyamoto, T., Murakami, R., Hamanishi, J., Tanigaki, K., Hosoe, Y., Mise, N., Takamatsu, S., Mise, Y., Ukita, M., Taki, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0407 · Cited by 161
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Algazi, A. P., Twitty, C. G., Tsai, K. K., Le, M., Pierce, R., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2217 · Cited by 147
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.